<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Advanced imaging technologies &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/advanced-imaging-technologies/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 14 Jan 2026 21:05:03 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Advanced imaging technologies &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Integrated Strategies for Bladder Cancer Decision Making</title>
		<link>https://bioengineer.org/integrated-strategies-for-bladder-cancer-decision-making/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 14 Jan 2026 21:04:37 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Advanced imaging technologies]]></category>
		<category><![CDATA[Artificial intelligence in oncology]]></category>
		<category><![CDATA[Bladder cancer diagnostics]]></category>
		<category><![CDATA[Multi-modal decision making]]></category>
		<category><![CDATA[personalized cancer therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/integrated-strategies-for-bladder-cancer-decision-making/</guid>

					<description><![CDATA[Bladder cancer continues to pose significant challenges on a global scale, primarily due to its intricate nature characterized by diagnostic uncertainty, exorbitant treatment expenses, and notably high recurrence rates. The current arsenal of diagnostic and treatment modalities, such as cystoscopy, transurethral resection of bladder tumors (TURBT), and standard histopathology, has revealed numerous shortcomings. These limitations [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">316958</post-id>	</item>
	</channel>
</rss>
